Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,893.00 JPY | +0.75% | +1.61% | +0.80% |
2023 | Niitaka Co., Ltd. acquired 90% stake in Biobank Co., Ltd. | CI |
2023 | Niitaka Co., Ltd. signed a letter of intent to acquire Keiyo Molasses Transportation Co., Ltd. | CI |
Fiscal Period: May | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 17.72B | 18.44B | 17.79B | 19.5B | 22.74B | |||||
Total Revenues | 17.72B | 18.44B | 17.79B | 19.5B | 22.74B | |||||
Cost of Goods Sold, Total | 10.21B | 10.28B | 10.5B | 12.82B | 14.6B | |||||
Gross Profit | 7.51B | 8.16B | 7.29B | 6.68B | 8.14B | |||||
Selling General & Admin Expenses, Total | 5.89B | 5.71B | 5.46B | 5.83B | 6.66B | |||||
Provision for Bad Debts | 85M | 9M | 6M | -2M | 4M | |||||
Other Operating Expenses, Total | 5.98B | 5.72B | 5.47B | 5.83B | 6.66B | |||||
Operating Income | 1.53B | 2.44B | 1.82B | 855M | 1.48B | |||||
Interest Expense, Total | -9M | -12M | -10M | -8M | -9M | |||||
Interest And Investment Income | 18M | 20M | 18M | 19M | 21M | |||||
Net Interest Expenses | 9M | 8M | 8M | 11M | 12M | |||||
Currency Exchange Gains (Loss) | 2M | -12M | -4M | - | -4M | |||||
Other Non Operating Income (Expenses) | 27M | 32M | 30M | 20M | 13M | |||||
EBT, Excl. Unusual Items | 1.57B | 2.47B | 1.86B | 886M | 1.5B | |||||
Gain (Loss) On Sale Of Investments | -39M | - | -55M | 10M | - | |||||
Gain (Loss) On Sale Of Assets | -2M | -1M | 8M | - | -1M | |||||
Asset Writedown | - | -1.06B | - | -38M | - | |||||
Other Unusual Items | 51M | 0 | - | 40M | -688M | |||||
EBT, Incl. Unusual Items | 1.58B | 1.41B | 1.81B | 898M | 809M | |||||
Income Tax Expense | 523M | 709M | 577M | 337M | 95M | |||||
Earnings From Continuing Operations | 1.06B | 697M | 1.23B | 561M | 714M | |||||
Net Income to Company | 1.06B | 697M | 1.23B | 561M | 714M | |||||
Minority Interest | - | - | - | - | -9M | |||||
Net Income - (IS) | 1.06B | 697M | 1.23B | 561M | 705M | |||||
Net Income to Common Incl Extra Items | 1.06B | 697M | 1.23B | 561M | 705M | |||||
Net Income to Common Excl. Extra Items | 1.06B | 697M | 1.23B | 561M | 705M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 179.21 | 118.06 | 208.52 | 95.03 | 119.42 | |||||
Basic EPS - Continuing Operations | 179.21 | 118.06 | 208.52 | 95.03 | 119.42 | |||||
Basic Weighted Average Shares Outstanding | 5.9M | 5.9M | 5.9M | 5.9M | 5.9M | |||||
Net EPS - Diluted | 179.21 | 118.06 | 208.52 | 95.03 | 119.42 | |||||
Diluted EPS - Continuing Operations | 179.21 | 118.06 | 208.52 | 95.03 | 119.42 | |||||
Diluted Weighted Average Shares Outstanding | 5.9M | 5.9M | 5.9M | 5.9M | 5.9M | |||||
Normalized Basic EPS | 166.32 | 261.07 | 196.39 | 93.8 | 157.07 | |||||
Normalized Diluted EPS | 166.32 | 261.07 | 196.39 | 93.8 | 157.07 | |||||
Dividend Per Share | 26 | 26 | 28 | 64 | 44 | |||||
Payout Ratio | 14.46 | 21.95 | 12.92 | 48.31 | 45.11 | |||||
Supplemental Items | ||||||||||
EBITDA | 2.12B | 3.07B | 2.44B | 1.43B | 2.02B | |||||
EBITA | 1.53B | 2.44B | 1.82B | 855M | 1.48B | |||||
EBIT | 1.53B | 2.44B | 1.82B | 855M | 1.48B | |||||
Effective Tax Rate - (Ratio) | 33.08 | 50.43 | 31.91 | 37.53 | 11.74 | |||||
Normalized Net Income | 982M | 1.54B | 1.16B | 554M | 927M | |||||
Non-Cash Pension Expense | -14.02M | -7.13M | -11.35M | -18.72M | 11.06M | |||||
Supplemental Operating Expense Items | ||||||||||
Selling and Marketing Expenses | 1.35B | 1.34B | 1.33B | 1.41B | 1.51B | |||||
Research And Development Expense From Footnotes | 304M | 295M | 209M | 270M | 303M |